| pubmed-article:11482502 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11482502 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:11482502 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11482502 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
| pubmed-article:11482502 | lifeskim:mentions | umls-concept:C0014822 | lld:lifeskim |
| pubmed-article:11482502 | lifeskim:mentions | umls-concept:C0079281 | lld:lifeskim |
| pubmed-article:11482502 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:11482502 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:11482502 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11482502 | pubmed:dateCreated | 2001-8-2 | lld:pubmed |
| pubmed-article:11482502 | pubmed:abstractText | The correction of anemia with human recombinant erythropoietin (rHuEPO) in end stage renal disease is associated with hypertension in about one third of hemodialysis patients. The pathogenesis of the rHuEPO-induced hypertension is still uncertain, though evidence of the involvement of endothelial cells has emerged. The aim of this study was to determine plasma endothelin-1 during hemodialysis and to compare the endothelin-1 levels in hemodialysis patients with and without rHuEPO substitution. Nineteen stable patients (13 male and 6 female, mean age 62 +/- 11 years) with end stage renal disease were studied. Cuprophan dialysers (GFS 12, Gambro, Lund, Sweden) were used for hemodialysis in all cases. rHuEPO (40 U/kg s.c.) was administered to 10 patients. Blood pressure (BP; RR mmHg) and blood volume changes (deltaBV; hemoglobinometry %) were serially measured. Samples were taken before and every hour during hemodialysis. Plasma endothelin-1 was measured by ELISA (R&D Systems, Minneapolis, USA) and corrected for hemoconcentration. Endothelin-1 concentration was elevated before commencement of hemodialysis (1.16 +/- 0.36 pg/ml) when compared to healthy controls (ref. 0.3-0.9) and increased to 1.47 +/- 0.51 pg/ml by the end of the session (p<0.05). In patients under rHuEPO-substitution plasma endothelin-1 was higher when compared to patients without substitution before (1.25 +/- 0.3 vs. 1.05 +/- 0.3 pg/ml) and at the end of HD (1.62 +/- 0.5 vs. 1.28 +/- 0.3 pg/ml, p<0.05). There was no difference in BP and deltaBV between the two groups during treatment. Plasma endothelin-1 was higher in hemodialysis patients and there was a continuous rise in plasma endothelin-1 during a session. Comparison of two groups of hemodialysis patients with and without s.c. rHuEPO-replacement treatment revealed a significantly higher plasma endothelin-1 concentration in patients with s.c. rHuEPO treatment. However, the elevated endothelin-1 levels were not accompanied by arterial hypertension. | lld:pubmed |
| pubmed-article:11482502 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11482502 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482502 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11482502 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482502 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482502 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482502 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11482502 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11482502 | pubmed:issn | 0391-3988 | lld:pubmed |
| pubmed-article:11482502 | pubmed:author | pubmed-author:WurtzBB | lld:pubmed |
| pubmed-article:11482502 | pubmed:author | pubmed-author:MannHH | lld:pubmed |
| pubmed-article:11482502 | pubmed:author | pubmed-author:BachRR | lld:pubmed |
| pubmed-article:11482502 | pubmed:author | pubmed-author:HeintzBB | lld:pubmed |
| pubmed-article:11482502 | pubmed:author | pubmed-author:StefanidisII | lld:pubmed |
| pubmed-article:11482502 | pubmed:author | pubmed-author:MertensP RPR | lld:pubmed |
| pubmed-article:11482502 | pubmed:author | pubmed-author:MakropoulosWW | lld:pubmed |
| pubmed-article:11482502 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11482502 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:11482502 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11482502 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11482502 | pubmed:pagination | 367-73 | lld:pubmed |
| pubmed-article:11482502 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:meshHeading | pubmed-meshheading:11482502... | lld:pubmed |
| pubmed-article:11482502 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11482502 | pubmed:articleTitle | Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis. | lld:pubmed |
| pubmed-article:11482502 | pubmed:affiliation | Medical Clinic II, Technical University Hospital, Aachen, Germany. stefanid@med.uth.gr | lld:pubmed |
| pubmed-article:11482502 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11482502 | pubmed:publicationType | Comparative Study | lld:pubmed |
